Core Insights - Teva Pharmaceutical Industries reported second-quarter 2025 adjusted earnings of 66 cents per share, exceeding the Zacks Consensus Estimate of 63 cents, with an 8% year-over-year increase in adjusted earnings driven by higher operating profits [1][7] - Revenues for the second quarter were $4.18 billion, falling short of the Zacks Consensus Estimate of $4.28 billion, remaining flat year over year on a reported basis and down 1% on a constant currency basis [1][2] Revenue Performance - Revenue growth was impacted as increased sales from branded drugs such as Austedo, Ajovy, and Uzedy were offset by declining generic drug sales in both U.S. and international markets, primarily due to the exit from Japan [2] - U.S. segment sales reached $2.15 billion, a 2% year-over-year increase, driven by branded drugs, although it missed the Zacks Consensus Estimate of $2.19 billion [3] - Generic/biosimilar product revenues in the U.S. declined 6% year over year to $961 million, missing the Zacks Consensus Estimate of $1.05 billion [4] Branded Drug Sales - Austedo sales in the U.S. were $495 million, up 22% year over year, although it missed the Zacks Consensus Estimate of $501.7 million [9] - Ajovy recorded sales of $63 million, a 53% year-over-year increase, surpassing the Zacks Consensus Estimate of $50.8 million [10] - Uzedy generated sales of $54 million, up 120% year over year, driven by volume growth [10] - Copaxone sales were $62 million, down 23% year over year, but exceeded the Zacks Consensus Estimate of $48.8 million [11] International Market Performance - Europe segment revenues were $1.3 billion, a 7% year-over-year increase, driven by higher revenues from Ajovy and generic products, beating the Zacks Consensus Estimate [12] - International Markets segment sales declined 17% year over year to $495 million, missing the Zacks Consensus Estimate of $602.4 million, primarily due to the divestment in Japan [13][14] Margin and Expense Analysis - Adjusted gross margin was 54.6%, up 170 basis points year over year, attributed to higher Austedo revenues and the sale of certain product rights [15] - Adjusted operating income rose 7% year over year to $1.13 billion, with an adjusted operating margin of 27.1% [17] Guidance Updates - Teva expects total revenues in 2025 to be between $16.8 billion and $17.2 billion, raising guidance for Austedo, Ajovy, and Uzedy sales [18][19] - Adjusted EPS is projected to be in the range of $2.5 to $2.65 per share for 2025, compared to the previous expectation of $2.45 to $2.65 [19]

Core Viewpoint - Alvotech (ALVO) is set to announce its Q2 2025 earnings results, with expectations of a loss per share of 26 cents and total revenues of $115.4 million [1][5]. Group 1: Revenue Segments - Alvotech recognizes revenues from two segments: Product revenue and License and other revenue [2]. - Product revenue comes from the sale of two approved biosimilars, Simlandi and Selarsdi, which are biosimilars to AbbVie's Humira and JNJ's Stelara, respectively [3]. Group 2: Market Performance - Investors are particularly interested in the sales figures for Simlandi and Selarsdi, which were launched in the U.S. in 2024 and Q1 2025, respectively, but have yet to gain significant market traction [4]. - Year-to-date, ALVO's shares have decreased by 26.5%, contrasting with the industry's growth of 0.6% [4]. Group 3: Pipeline Developments - Alvotech's pipeline includes AVT05, AVT06, and AVT03, with multiple regulatory filings currently under review in the U.S. and EU [5]. - AVT05 is being developed as a proposed biosimilar to JNJ's Simponi, with regulatory decisions expected by the end of the year [7]. - AVT06 is a proposed biosimilar to Bayer and Regeneron's Eylea, with decisions anticipated by the end of 2025 [8]. - AVT03 is a biosimilar candidate to Amgen's Prolia and Xgeva, with the FDA accepting a regulatory filing for review in March 2025 [9]. Group 4: Partnership Expansions - Alvotech and Dr. Reddy's Laboratories have expanded their partnership to co-develop a biosimilar candidate to Merck's Keytruda [10]. Group 5: Earnings Surprise History - Alvotech has a strong earnings surprise history, having beaten estimates in the last three quarters with an average surprise of 244.18% [11]. - In the last reported quarter, the company achieved an earnings surprise of 305.88% [12]. Group 6: Earnings Predictions - Alvotech currently has an Earnings ESP of 0.00%, indicating no predictive advantage for an earnings beat this time [14].

Core Viewpoint - Teva Pharmaceutical Industries reported mixed first-quarter 2025 results, beating earnings estimates but missing revenue expectations, with adjusted earnings of 52 cents per share and revenues of $3.89 billion [1][16]. Financial Performance - Adjusted earnings increased by 8% year over year, driven by higher operating profits [1]. - Total revenues rose 2% year over year on a reported basis and 5% on a constant currency basis [1]. - U.S. segment sales reached $1.91 billion, an 11% increase year over year, surpassing estimates [2]. Product Performance - Revenues from generic products in the U.S. rose 5% to $849 million, primarily due to the launch of Simlandi, a generic version of Humira [3][4]. - Sales of Austedo, a Huntington's disease drug, increased by 40% year over year to $396 million, exceeding estimates [6]. - Ajovy sales grew 18% year over year to $53 million, while Uzedy generated $39 million in sales [7]. Regional Performance - Europe segment revenues declined 6% year over year to $1.19 billion, missing estimates [9][10]. - International Markets segment sales decreased 2% year over year to $582 million, also missing estimates [11]. Guidance and Future Outlook - Teva expects total revenues for 2025 to be between $16.8 billion and $17.2 billion, slightly lowering the upper end of the previous guidance [13]. - Adjusted EPS guidance for 2025 was raised to a range of $2.45-$2.65 per share [13]. - The company anticipates $700 million in cost savings by 2027, with an adjusted operating margin target of 30% [15]. Market Reaction - Following the earnings release, Teva's stock rose over 9%, despite a year-to-date decline of 20.1% compared to the industry decline of 17.6% [19].

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech’s ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson’s JNJ Stelara (ustekinumab).As of April 30, 2025, Selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis.Also ...